IMR Press / CEOG / Special Issues / 1599613294886

Gynecological Tumors

Submission deadline: 31 December 2021
Special Issue Editors
Michail Varras, MD
Obstetrics and Gynecology Department, "Elena Venizelou" General Hospital, Athina, Greece
Interests: Gynaecological oncology; Minimal invasive gynaecological surgery; Reproductive medicine; Mocecular biology of placenta; Rare obstetrics and gynaecology Clinical cases
Special Issue Information

Dear Colleagues,

The pathogenesis of cancer is a complex process, whose occurence and development involve multiple pathways and numerous genetic alterations such as gene mutations, amplifications and chromosomal translocations or rearrangements. Gynecological malignant tumors exibit very heterogeneity including various histological types with different molecular characteristics, genetic risk factors and clinical behaviors. Inhibition of the oncogenic pathways is currently under clinical trials for the therapy of gynecological malignant tumors. Detection of several molecular biomarkers in the tumors of the female genital tract could provide more information about the underlying mechanisms of cancer proliferation, invasion, persistance, metastasization and recurrence. Ovarian carcinoma is one of the deadly causes of gynecological cancer worldwide because the disease in advanced-stage consistently relapse despite surgical resection and chemotherapy combination. In patients with endometrial carcinoma, the clinicians should take into consideration multiple factors, which may affect therapeutic options in order to determine the appropriate therapeutic regimens to avoid over- or under–treatment. Various tumor-suppressor genes, oncogenes and tumor growth factors apart from high-risk HPV infection are involved in cervical carcinogenesis. The prognosis of patients with advanced stage cervical carcinoma remains poor despite treatment schedules with combination of radiotherapy and chemotherapy. Actually, one of the causes of cervical cancer relapse is the high levels of radiation during radiotherapy. Therefore there is an urgent need to discover and identify several anticancer potential molecules for development of effective novel targeted therapies in order to suppress cell growth and metastasis of gynecological malignant tumors.

The goal of this special issue is to discover further the mechanisms of tumorogenesis in human uterus, ovaries, fallopian tubes, vulva and vagina on cell proliferation, survival and failure to undergo an appropriate apoptosis. Also, the aim of this special issue is to publish both original articles and comprehensive reviews about the potential association between the expression of molecular tumor biomarkers and the clinicopathological characteristics of patients with gynecological malignant tumors, their treatment options and prognosis. Furthermore, this special issue will address the environmental, genetic and cellular mechanisms of common benign gynecological tumors including uterine leiomyomas and endometriomas and the specific gene therapy protocols, especially for women who want to preserve their fertility.

Dr. Michail Varras

Guest Editor

Keywords
Gynecological tumor
Benign
Malignant
Uterine leiomyoma
Endometrioma
Oncogene
Tumor suppressor gene
Biomarker
cell apoptosis
Expression
Signaling
Treatment
Gene therapy
Clinicopathological analysis
Prognosis
Resistance
Survival
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Planned Paper (3 Papers)
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to IMR Press journals will subject to peer-review before acceptance

Endometrial carcinomas: Genomic-based pathways to tumorigenesis and biological tissue biomarkers with potential prognostic and clinical significance

Dr. Michail Varras

Prognostic significance of molecular alterations in ovarian carcinomas

Dr. Michail Varras

Molecular tumorigenesis, tissue biomarkers and clinical characteristics of human cervical carcinomas: Implications for diagnosis, personalized therapeutic strategies, prognosis and future potential

 Dr. Michail Varras

Back to top